Harry Kopelman, MD
HAK Consulting LLC
Dr. Kopelman has had a distinguished career in cardiology for the better part of four decades. He has gained national recognition as a key opinion leader and innovator in the realm of clinical cardiac electrophysiology.
Dr. Kopelman founded the cardiac electrophysiology program and directed the first dedicated cardiac electrophysiology laboratory in Georgia at St Joseph’s Hospital of Atlanta, where he performed the first successful catheter ablation for PSVT. Following that, he was an inaugural member and held leadership positions at the Piedmont Heart Institute (PHI) including directing the cardiac electrophysiology laboratories and as a member of the PHI Board of Directors and President’s Council.
Dr. Kopelman has contributed to the scientific and medical literature in the fields of both preclinical and clinical research. His broad areas of interest have included clinical cardiac electro-pharmacology, cardiac ablation and 3D electroanatomical cardiac mapping and reconstruction, cardiac rhythm device development, and remote arrhythmia monitoring. In addition to his substantial contributions in the clinical realm, Dr. Kopelman has advised the device industry for several decades, including chairing the Medical Advisory Board for LifeWatch AG and membership in Easton Capital Partners’ Scientific Advisory Board.
Dr. Kopelman received his MD from Georgetown University School of Medicine and interned in internal medicine at UNC-Chapel Hill. After residency there, he completed dual fellowships in cardiovascular diseases and cardiac electrophysiology at Vanderbilt University. Following that, Dr. Kopelman accepted a position at the Philadelphia Heart Institute with an academic appointment at the University of Pennsylvania. He is board certified in internal medicine, cardiovascular disease, and clinical cardiac electrophysiology, and is a Fellow of the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society.
Since retiring from PHI, Dr. Kopelman has focused on consulting practices and advising companies in the cardiovascular space, including Milestone Pharmaceuticals.